

# Franziska Di Pauli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/566288/publications.pdf>

Version: 2024-02-01

68  
papers

1,184  
citations

394421

19  
h-index

414414

32  
g-index

69  
all docs

69  
docs citations

69  
times ranked

1533  
citing authors

#	ARTICLE	IF	CITATIONS
1	Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. <i>Clinical Immunology</i> , 2011, 138, 247-254.	3.2	180
2	Fulminant demyelinating encephalomyelitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e175.	6.0	75
3	Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 196-203.	3.0	67
4	Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study. <i>PLoS ONE</i> , 2016, 11, e0158978.	2.5	56
5	Discontinuation of disease-modifying therapies in multiple sclerosis – Clinical outcome and prognostic factors. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1241-1248.	3.0	56
6	Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Austria. <i>Multiple Sclerosis Journal</i> , 2020, 26, 69-78.	3.0	51
7	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders: Toward a New Spectrum of Inflammatory Demyelinating CNS Disorders?. <i>Frontiers in Immunology</i> , 2018, 9, 2753.	4.8	49
8	Multiple sclerosis and COVID-19: How many are at risk?. <i>European Journal of Neurology</i> , 2021, 28, 3369-3374.	3.3	37
9	Macular ganglion cell – inner plexiform layer thinning as a biomarker of disability progression in relapsing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 684-694.	3.0	36
10	Change of olfactory function as a marker of inflammatory activity and disability progression in MS. <i>Multiple Sclerosis Journal</i> , 2019, 25, 267-274.	3.0	29
11	To treat or not to treat: Sequential individualized treatment evaluation in relapsing multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 39, 101908.	2.0	29
12	Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study. <i>PLoS ONE</i> , 2017, 12, e0174005.	2.5	29
13	COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registry. <i>PLoS ONE</i> , 2021, 16, e0255316.	2.5	27
14	Cerebrospinal fluid B cells and disease progression in multiple sclerosis - A longitudinal prospective study. <i>PLoS ONE</i> , 2017, 12, e0182462.	2.5	26
15	Kappa-Free Light Chains in CSF Predict Early Multiple Sclerosis Disease Activity. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	26
16	Serum neurofilament levels correlate with retinal nerve fiber layer thinning in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1682-1690.	3.0	25
17	Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2209-2218.	3.0	25
18	Features of intrathecal immunoglobulins in patients with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2010, 288, 147-150.	0.6	23

#	ARTICLE	IF	CITATIONS
19	Validation of inter-eye difference thresholds in optical coherence tomography for identification of optic neuritis in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102403.	2.0	22
20	Smelling multiple sclerosis: Different qualities of olfactory function reflect either inflammatory activity or neurodegeneration. <i>Multiple Sclerosis Journal</i> , 2020, 26, 57-68.	3.0	20
21	Transient impairment of olfactory threshold in acute multiple sclerosis relapse. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 23, 74-77.	2.0	19
22	Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 43, 102155.	2.0	18
23	Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score. <i>European Journal of Neurology</i> , 2021, 28, 1609-1616.	3.3	18
24	Differential Binding of Autoantibodies to MOG Isoforms in Inflammatory Demyelinating Diseases. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	16
25	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1424-1456.	3.0	16
26	Retinal layer thinning is reflecting disability progression independent of relapse activity in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020, 6, 205521732096634.	1.0	15
27	Impairment of odor discrimination and identification is associated with disability progression and gray matter atrophy of the olfactory system in MS. <i>Multiple Sclerosis Journal</i> , 2020, 26, 706-715.	3.0	14
28	Cerebrospinal fluid protein in Guillain-Barré syndrome: Need for age-dependent interpretation. <i>European Journal of Neurology</i> , 2021, 28, 965-973.	3.3	12
29	Cerebrospinal Fluid Findings in 541 Patients With Clinically Isolated Syndrome and Multiple Sclerosis: A Monocentric Study. <i>Frontiers in Immunology</i> , 2021, 12, 675307.	4.8	12
30	Comparing humoral immune response to SARS-CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study. <i>European Journal of Neurology</i> , 2022, 29, 1538-1544.	3.3	12
31	Rethinking the importance of paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis: They do matter. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 9, 150-154.	2.0	11
32	New clinical implications of anti-myelin oligodendrocyte glycoprotein antibodies in children with CNS demyelinating diseases. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 22, 35-37.	2.0	11
33	Progressive multifocal leukoencephalopathy complicating untreated chronic lymphatic leukemia: Case report and review of the literature. <i>Journal of Clinical Virology</i> , 2014, 60, 424-427.	3.1	10
34	Retinal layer thinning predicts treatment failure in relapsing multiple sclerosis. <i>European Journal of Neurology</i> , 2021, 28, 2037-2045.	3.3	10
35	Dream Content in Patients With Sleep Apnea: A Prospective Sleep Laboratory Study. <i>Journal of Clinical Sleep Medicine</i> , 2018, 14, 41-46.	2.6	9
36	Long-term outcome after COVID-19 infection in multiple sclerosis: A nationwide multicenter matched-control study. <i>European Journal of Neurology</i> , 2022, 29, 3050-3060.	3.3	9

#	ARTICLE	IF	CITATIONS
37	Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial. <i>Journal of Neuroimmunology</i> , 2015, 287, 98-105.	2.3	8
38	Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry. <i>Journal of Neurology</i> , 2021, 268, 4303-4310.	3.6	8
39	Conversion and reversion of anti-John Cunningham virus antibody serostatus: A prospective study. <i>Brain and Behavior</i> , 2019, 9, e01332.	2.2	7
40	Cerebrospinal fluid oligoclonal bands in Neuroborreliosis are specific for <i>Borrelia burgdorferi</i> . <i>PLoS ONE</i> , 2020, 15, e0239453.	2.5	7
41	Serum neurofilament light levels correlate with change of olfactory function in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731988598.	1.0	6
42	Pregnancy Outcomes in Patients With Multiple Sclerosis Exposed to Natalizumab—A Retrospective Analysis From the Austrian Multiple Sclerosis Treatment Registry. <i>Frontiers in Neurology</i> , 2020, 11, 676.	2.4	5
43	Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma. <i>Frontiers in Immunology</i> , 2020, 11, 515556.	4.8	5
44	Estimating Risk of Multiple Sclerosis Disease Reactivation in Pregnancy and Postpartum: The VIPRiMS Score. <i>Frontiers in Neurology</i> , 2021, 12, 766956.	2.4	5
45	Retinal layer thinning as a biomarker of long-term disability progression in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1871-1880.	3.0	5
46	Experiences in treatment of multiple sclerosis with natalizumab from a real-life cohort over 15 years. <i>Scientific Reports</i> , 2021, 11, 23317.	3.3	4
47	Alemtuzumab induced hemodynamic change in relapsing multiple sclerosis occurs independent of corticosteroid premedication—a retrospective multicentre study. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103810.	2.0	4
48	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and Varicella Zoster Virus Infection - Frequency of an Association. <i>Frontiers in Immunology</i> , 2021, 12, 769653.	4.8	3
49	Olfactory threshold predicts treatment response in relapsing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1541-1552.	3.0	3
50	Sudomotor dysfunction in people with neuromyelitis optica spectrum disorders. <i>European Journal of Neurology</i> , 2022, 29, 2772-2780.	3.3	3
51	Smoking is not associated with higher prevalence of JC virus in MS patients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 907-910.	2.9	2
52	Inner nuclear layer and olfactory threshold are interlinked and reflect inflammatory activity in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020, 6, 205521732094573.	1.0	2
53	Influence of physical activity on serum vitamin D levels in people with multiple sclerosis. <i>PLoS ONE</i> , 2020, 15, e0234333.	2.5	2
54	Paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis do not indicate benign prognosis—The PaSiMS II study. <i>PLoS ONE</i> , 2017, 12, e0181458.	2.5	2

#	ARTICLE	IF	CITATIONS
55	Natalizumab treatment during pregnancy in multiple sclerosis – clinical and bioethical aspects of an ongoing debate. Wiener Medizinische Wochenschrift, 2022, , 1.	1.1	2
56	Impact of Disease-Modifying Treatments on the Longitudinal Evolution of Anti-JCV Antibody Index in Multiple Sclerosis. Frontiers in Immunology, 2018, 9, 2435.	4.8	1
57	Transverse myelitis as a rare presentation of antiphospholipid-antibody-associated disorders. Multiple Sclerosis and Related Disorders, 2020, 45, 102405.	2.0	0
58	Recovery of Chronic Inflammatory Demyelinating Polyneuropathy on Treatment With Ocrelizumab in a Patient With Co-Existing Multiple Sclerosis. Journal of Central Nervous System Disease, 2022, 14, 117957352210848.	1.9	0
59	Influence of physical activity on serum vitamin D levels in people with multiple sclerosis. , 2020, 15, e0234333.		0
60	Influence of physical activity on serum vitamin D levels in people with multiple sclerosis. , 2020, 15, e0234333.		0
61	Influence of physical activity on serum vitamin D levels in people with multiple sclerosis. , 2020, 15, e0234333.		0
62	Influence of physical activity on serum vitamin D levels in people with multiple sclerosis. , 2020, 15, e0234333.		0
63	Influence of physical activity on serum vitamin D levels in people with multiple sclerosis. , 2020, 15, e0234333.		0
64	Influence of physical activity on serum vitamin D levels in people with multiple sclerosis. , 2020, 15, e0234333.		0
65	Cerebrospinal fluid oligoclonal bands in Neuroborreliosis are specific for Borrelia burgdorferi. , 2020, 15, e0239453.		0
66	Cerebrospinal fluid oligoclonal bands in Neuroborreliosis are specific for Borrelia burgdorferi. , 2020, 15, e0239453.		0
67	Cerebrospinal fluid oligoclonal bands in Neuroborreliosis are specific for Borrelia burgdorferi. , 2020, 15, e0239453.		0
68	Cerebrospinal fluid oligoclonal bands in Neuroborreliosis are specific for Borrelia burgdorferi. , 2020, 15, e0239453.		0